Superficial transitional cell carcinoma of the urinary bladder Cancer Superficial transitional cell carcinoma of the urinary bladder
Conditions
Interventions
Allopurinol 100 mg once daily with food or placebo drug
Sponsors
Leicester General Hospital (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with solitary Transitional Cell Carcinoma (TCC) Ta or T1 bladder tumour (Grade one to two) that recurs at three months 2. Patients with multifocal TCC Ta bladder tumours (Grade one to two) that do not recur at three months 3. Patients with multifocal TCC Ta bladder tumours (Grade one to two) that recurs at three months
Exclusion criteria
Exclusion criteria: 1. Tumours with a higher risk of progression to muscle-invasive bladder cancer 2. Non-TCC bladder cancer 3. Multifocal T1 or Grade three TCC 4. Carcinoma in situ 5. More than one instillation of intravesical chemotherapy 6. Intravesical Bacillus Calmette-Guerin (BCG) therapy Other reasons: 1. Current azathioprine or mercaptopurine treatment 2. Serum creatinine more than 200 µmol/l 3. Pregnant 4. Breast feeding 5. Aged under 18 year of age 6. Previous Allopurinol hypersensitivity 7. Current allopurinol treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to biopsy-proven bladder tumour recurrence whilst taking allopurinol 100 mg once daily or placebo. | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the tolerability of allopurinol in patients with superficial bladder cancer, and to identify any adverse events. | — |
Countries
United Kingdom
Outcome results
None listed